logo

BCAX

Bicara Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.25 / 10
Netural

Fund-flow and analyst sentiment together lean bullish. The fund-flow score is 7.59/10, signaling robust liquidity despite a negative trend in block and large-size flows. Analyst consensus is 100% Buy across two institutions, although historical win rates are modest (0-33%). This combination suggests underlying institutional interest that could support price stabilization, even if short-term price action remains choppy.

FundamentalSentiment(4.25)Technical
Fund Flow Rating
Analyst RatingBuy

Wall Street Opinions

Buy

Strong Buy

0%

Buy

100%

Hold

0%

Sell

0%

Strong Sell

0%

Date2026-01-13
InstitutionWedbush
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of BCAX?
  • BCAX holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.25/10 (Netural).